AIMS: This study considers the cost-effectiveness of @entity2179 in @entity712 @entity1 as an adjunctive therapy to usual treatment. METHODS AND RESULTS: A cost-effectiveness model was constructed using data available from the CIBIS I _ II trials and other secondary sources. Differences in @entity1 survival rates were calculated for @entity2179 (n=1327) and placebo groups (n=1320) extrapolating data over a 5-year period, under limited and extended benefits scenarios to calculate @entity1017 ( @entity1017 ). Hospitalisation rates were calculated using data from both CIBIS trials. Costs were considered under two different @entity1 management protocols for treatment initiation - shared care by outpatient clinics and GPs and initiation by a nurse working in the community. Discounted @entity1017 were calculated to be 0.228 under the limited benefits scenario and 0.368 under the extended benefits scenario. Under the extended benefits scenario shared care resulted in a cost of pound268 per @entity1017 or pound412 per @entity1017 for community initiation. Under the limited benefits scenario the costs were a pound135 saving and pound69, respectively. CONCLUSION: This analysis has shown @entity2179 to be an economically attractive therapy in comparison with other treatments. It is hoped that its adoption by clinicians will be rapid, despite the labour intensive and time consuming up-titration process involved in its initiation.

A cost-effectiveness analysis of @entity2179 for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity2179 :: ('MESH:D017298', 'Chemical') :: ['bisoprolol'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['LYG', 'life years gained']
@entity712 :: (MESH:D006333,Disease) :: ['heart failure']
